CSIMarket
 


Vir Biotechnology Inc   (VIR)
Other Ticker:  
 

Vir Biotechnology Inc 's Quick Ratio

VIR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




VIR Quick Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 31.87 % 227.25 % 94.51 % 244.47 % 203.55 %
Y / Y Cash & cash equivalent Change 201.04 % 160.78 % 65.39 % -22.99 % -7.15 %
Quick Ratio MRQ 7.58 4.55 1.75 1.68 3.32
Overall Ranking # # # # #
Seq. Current Liabilities Change -35.5 % -31.96 % 105.82 % 46 % 60.06 %
Seq. Cash & cash equivalent Change 7.56 % 77.11 % 113.84 % -26.1 % -6.83 %



Quick Ratio third quarter 2022 Comment
Vir Biotechnology Inc 's Cash & cash equivalent grew by 7.56 % in the III. Quarter sequntially, while Current Liabilities decreased, this led to improvement in Vir Biotechnology Inc 's Quick Ratio to 7.58, above Vir Biotechnology Inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry Vir Biotechnology Inc booked the highest Quick Ratio than Vir Biotechnology Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Quick Ratio?
What are VIR Segments?
See Quick Ratio VIR on the trailing twelve month basis
Quick Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Vir Biotechnology Inc 's Current Liabilities $ 308 Millions Visit VIR's Balance sheet
Vir Biotechnology Inc 's Cash & cash equivalent $ 2,337 Millions Visit VIR's Balance sheet
Source of VIR's Sales Visit VIR's Sales by Geography


Cumulative Vir Biotechnology Inc 's Quick Ratio

VIR's Quick Ratio for the trailling 12 Months

VIR Quick Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 31.87 % 227.25 % 94.51 % 244.47 % 203.55 %
Y / Y Cash & cash equivalent TTM Growth 201.04 % 160.78 % 65.39 % -22.99 % -7.15 %
Quick Ratio TTM 3.45 2.71 2.4 2.7 3.69
Total Ranking TTM # 358 # 1268 # 1416 # 1332 # 650
Seq. Current Liabilities TTM Growth -35.5 % -31.96 % 105.82 % 46 % 60.06 %
Seq. Cash & cash equivalent TTM Growth 7.56 % 77.11 % 113.84 % -26.1 % -6.83 %


TTM Quick Ratio Comment
On the trailing twelve months basis VIR Cash & cash equivalent average more than doubled by 201.04 % in III. Quarter year on year, faster than Current Liabilities, this led to increase in in Vir Biotechnology Inc 's Quick Ratio to 3.45, Quick Ratio remained below VIR average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 64 other companies have achieved higher Quick Ratio than Vir Biotechnology Inc . While overall ranking remained unchanged compare to previous quarter at no. 358.

Explain Quick Ratio?
What are VIR Segments?
See Quick Ratio VIR on the trailing twelve month basis

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 65
Healthcare Sector # 237
Within the Market # 358


TTM Quick Ratio Statistics
High Average Low
8.73 5.11 2.4
(Dec 31 2020)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Rewalk Robotics Ltd   20.48 $ 74.027  Millions$ 3.614  Millions
Celldex Therapeutics inc   19.86 $ 323.471  Millions$ 16.287  Millions
Vor Biopharma Inc   18.53 $ 136.067  Millions$ 7.345  Millions
Fusion Pharmaceuticals Inc   17.15 $ 205.481  Millions$ 11.981  Millions
Icosavax Inc   16.99 $ 221.399  Millions$ 13.033  Millions
4d Molecular Therapeutics Inc   16.79 $ 227.715  Millions$ 13.564  Millions
Organovo Holdings Inc   16.72 $ 23.220  Millions$ 1.389  Millions
Vaxcyte Inc   16.02 $ 362.226  Millions$ 22.614  Millions
Replimune Group Inc   15.80 $ 371.820  Millions$ 23.537  Millions
Kymera Therapeutics Inc   15.19 $ 481.908  Millions$ 31.729  Millions
Cardiff Oncology inc   15.10 $ 114.303  Millions$ 7.571  Millions
Candel Therapeutics Inc   14.17 $ 77.183  Millions$ 5.446  Millions
Krystal Biotech Inc   14.07 $ 394.420  Millions$ 28.032  Millions
Entera Bio Ltd   13.46 $ 14.323  Millions$ 1.064  Millions
Tracon Pharmaceuticals inc   13.28 $ 17.037  Millions$ 1.283  Millions
Century Therapeutics inc   13.23 $ 355.859  Millions$ 26.907  Millions
Immunovant Inc   12.77 $ 405.773  Millions$ 31.784  Millions
Allovir Inc   12.75 $ 264.107  Millions$ 20.719  Millions
Quince Therapeutics Inc   12.65 $ 62.534  Millions$ 4.945  Millions
Talis Biomedical Corporation  12.64 $ 143.783  Millions$ 11.378  Millions
Compass Therapeutics Inc   12.59 $ 120.602  Millions$ 9.578  Millions
Crispr Therapeutics Ag  12.57 $ 1,895.975  Millions$ 150.870  Millions
Monte Rosa Therapeutics Inc   12.49 $ 272.149  Millions$ 21.790  Millions
Rubius Therapeutics Inc   11.92 $ 103.884  Millions$ 8.717  Millions
Allogene Therapeutics Inc   11.30 $ 552.229  Millions$ 48.872  Millions
Aura Biosciences Inc   11.21 $ 111.701  Millions$ 9.964  Millions
Vicarious Surgical Inc   10.86 $ 126.797  Millions$ 11.678  Millions
Ginkgo Bioworks Holdings Inc   10.44 $ 1,302.603  Millions$ 124.818  Millions
Pacific Biosciences Of California Inc   10.22 $ 834.340  Millions$ 81.649  Millions
Scholar Rock Holding Corp  10.19 $ 343.655  Millions$ 33.736  Millions

Date modified: 2022-11-06T04:16:49+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RVYL's Profile

Stock Price

RVYL's Financials

Business Description

Fundamentals

Charts & Quotes

RVYL's News

Suppliers

RVYL's Competitors

Customers & Markets

Economic Indicators

RVYL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071